404: What RevMed's pancreatic cancer drug meant for one patient

Biotech market volatility and clinical breakthroughs from the ASCO conference define the current industry landscape. A significant sector-wide sell-off occurred despite positive maintenance trial data for Abivax’s ulcerative colitis treatment, which faced investor scrutiny over unrelated malignancy reports. Meanwhile, clinical data for ivonescimab demonstrated a 34% reduction in death risk for non-small cell lung cancer patients, though questions regarding the translatability of Chinese trial results to global populations persist. Eli Lilly’s acquisition of Cullinan Oncology highlights the growing promise of in vivo CAR T-cell therapies, which recently showed complete response rates in multiple myeloma patients. Leanna Stokes, a patient with metastatic pancreatic cancer, provides a personal perspective on the life-extending benefits of Revolution Medicines’ divarasib, emphasizing that even modest improvements in survival statistics represent meaningful, life-restoring outcomes for patients navigating terminal diagnoses.